ALXO (ALX Oncology Holdings) LT-Debt-to-Total-Asset : 0.05 (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is ALX Oncology Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. ALX Oncology Holdings's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.05.

ALX Oncology Holdings's long-term debt to total assets ratio increased from Sep. 2023 (0.04) to Sep. 2024 (0.05). It may suggest that ALX Oncology Holdings is progressively becoming more dependent on debt to grow their business.

ALX Oncology Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for ALX Oncology Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ALX Oncology Holdings LT-Debt-to-Total-Asset Chart

ALX Oncology Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.51

0.03

0.06

ALX Oncology Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.06	0.05	0.05	0.05

ALX Oncology Holdings LT-Debt-to-Total-Asset Calculation

ALX Oncology Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	15.622	/	242.553
	=

ALX Oncology Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	9.835	/	185.715
	=

ALX Oncology Holdings (NAS:ALXO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

ALX Oncology Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of ALX Oncology Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ALX Oncology Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ALX Oncology Holdings Inc (NAS:ALXO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

323 Allerton Avenue, South San Francisco, CA, USA, 94080

Website

https://www.alxoncology.com

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Executives

Shelly Pinto	officer: VP, Finance and CAO	866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jaume Pons	director, officer: President and CEO	C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Rekha Hemrajani	director	3928 POINT EDEN WAY, HAYWARD CA 94545
Sophia Randolph	officer: Chief Medical Officer	C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Peter S Garcia	officer: Chief Financial Officer	ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jason Lettmann	director, 10 percent owner	C/O RA PHARMACEUTICALS, INC., 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
J. Scott Garland	director	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Itziar Canamasas	director	C/O ALX ONCOLOGY HOLDINGS INC, 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Lsv Associates, Llc	10 percent owner	2884 SAND HILL ROAD, SUITE 121, MENLO PARK CA 94025
G. Walmsley Graham	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Vivo Opportunity Fund, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Goodman Corey S	director, 10 percent owner, other: Executive Chairman	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Fund, L.p.	10 percent owner, other: See Remarks	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Vivo Opportunity, Llc	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Capital Fund Ix, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301